Deciding on treatment for pulmonary fibrosis
Part of Lungs & breathing clinical trials.
This study looks at how patients and doctors decide on treatment for pulmonary fibrosis. It aims to understand the impact of side effects from antifibrotic medicines on treatment choices.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a diagnosis of pulmonary fibrosis (including IPF or PPF)
- You are at least 18 years old and receive outpatient care
- You have taken or are currently taking pirfenidone, nintedanib, or nerandomilast
- You have experienced at least one side effect from your antifibrotic medicine
- You are not currently in another interventional clinical trial
- You have not had a lung transplant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses safe, painless scans (like muscle ultrasound and a body composition test) to track changes in muscle and fat in patients with IPF or PPF who are starting anti-fibrotic medication. The goal is to better understand how these treatments affect your body.
This trial tests an oral medication, ifetroban, to see if it can slow the progression of idiopathic pulmonary fibrosis (IPF), a lung condition that causes scarring. It aims to improve breathing and lung function in patients with IPF.
This trial tests an inhaled form of nintedanib (a drug that helps slow lung scarring) for people with idiopathic pulmonary fibrosis (IPF). It may be an option for those newly diagnosed or already on stable treatment.
This study tests artesunate, a medicine that may help treat idiopathic pulmonary fibrosis (IPF), a condition that causes lung scarring. It is for people who are already taking other IPF treatments and want to see if adding artesunate can improve their condition.
This study tests an experimental medicine called HSK44459 to see if it can slow down progressive pulmonary fibrosis (PPF), a condition that causes lung scarring and breathing difficulty. The goal is to learn if the medicine can help people keep more of their lung function compared to a placebo.
This study builds a community registry to learn about people affected by pulmonary fibrosis and related lung conditions, including patients, caregivers, and close family. By joining, you help researchers better understand needs and experiences in the real world.
Hear when a new Pulmonary Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.